|
Country: Netherlands
City: Utrecht
IHTC:
Van Creveldkliniek and Hematology
University Medical Centre Utrecht
P.O. Box 85500, Huispostnr. CO1.425
3508 GA Utrecht, CX
Netherlands
Tel.: 31 88 755 8540 (office hours)
Tel.: 31 88 755 5555
Fax: 31 88 755 5438
Email: R.Schutgens@umcutrecht.nl
Website: http://www.vancreveldkliniek.nl/
Director:
Medical Staff: R. Schutgens, K. Fischer, Evelien Mauser-Bunschoten, G. Roosendaal
Responsible for training: Evelien Mauser-Bunschoten, L. Heijnen, Goris Roosendaal, P. de Kleijn, E. Haan
Year of IHTC designation: 1996
Areas of specialty: General hemophilia care for children and adults; treatment of inhibitors; physcal therapy; orthopedic surgery; rehabilitation; laboratory diagnotics; genetic counseling; nursing; social work; epidemiology.
DESCRIPTION OF TRAINING PROGRAM
Clinical activities: Participation in patient care for children and adults. The Van Creveldkliniek is responsible for the care of over 800 patients with hemophilia and allied bleeding disorders. Services include a large prophylactic program, orthopedic surgery, and programs for hepatitis C infection, and genetic counseling.
Laboratory activities/research: All coagulation tests, extensive research programs in the field of coagulation, research of pathogenesis of arthopathy.
Multidisciplinary activities/research: The Van Creveldkliniek has a multidisciplinary team of workers with all the disciplines involved in hemophilia care.
Additional information: The Van Creveldkliniek has a strong research program in hemophilia. Also it has initiated multicentre studies for hemophilia such as the PedNet registry and the Rodin study. The center can train up to two fellows annually.
DESCRIPTION OF IHTC FACILITIES
Climate: Temperate Sea Climate
Language: English, Dutch and German
Financial assistance: Dependent on WFH funds
RELEVANT PUBLICATIONS BY IHTC STAFF
Total knee arthroplasty in haemophilic arthropathy; efficiency of clotting factor usage in multi-joint procedures.
Schild FJ, Mauser-Bunschoten EP, Verbout AJ, van Rinsum AC, Roosendaal G. 2009; 7; 1741–1756
Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment.
DEN Uijl I, Mauser-Bunschoten EP, Roosendaal G, Schutgens R, Fischer K. Haemophilia. 2009; 15, 1215–1218
Risk stratification of patients with pulmonary embolism based on pulse rate and D-dimer concentration.
Agterof MJ, van Bladel ER, Schutgens RE, Snijder RJ, Tromp EA, Prins MH, Biesma DH. Thrombosis and Haemostasis. 2009; 102(4):683-687.
Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy
Mauser-Bunschoten EP, Fransen van de Putte DE, Schutgens REG
Haemophilia. 2009; 15; 853–863
Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline
Schutgens REG, Tuinenburg A, Roosendaal G, Hoseyni Guyomi S, Mauser-Bunschoten EP. Haemophilia. 2009; 15; 952-958
Updated November 2009
|
